# Katalyst Securities

> Katalyst Securities is a VC fund backing Fitness, Medical and Genetics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 2
- Last investment: Nov 2021
- Lead investor: 50%
- Last updated: Aug 2026
- Website: http://www.katalystsecuritiesllc.com

Katalyst Securities is an independent brokerage firm specializing in private equity investments. The firm provides financial services to a diverse client base of corporations, investment funds, and high net worth individuals. It buys and sells securities such as stocks, bonds, mutual funds, and other investment products.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Fitness | 1 | 50% |
| Medical | 1 | 50% |
| Genetics | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Violet Defense | Violet Defense is on a journey to find new ways to protect people from harmful germs that have grown resistant to traditional forms of cleaning and disinfecting. After years of research, Mark discovered a unique way to combine a light source with a highly transmissive lens material to produce greater photonic energy. Because the lens can withstanddirect and immediate contact with the light source, we have the ability to miniaturize the technology deployment. Mark secured extensive worldwide patent protection for this breakthrough discovery.In 2012, Mark founded Violet Defense to research and develop new products using this patented technology that can help protect our world from germs. The first line, Surface Air Germ Elimination (S.A.G.E.) System hit the market in May 2017. The possibilities of where this technology goes from here are endless. | $20M | Series B | Nov 02, 2021 |  |
| Exicure | Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M |  | Sep 27, 2017 |  |

2 of 2 investments shown.

## Co-investors
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 1 deal together
- [Kirenaga Partners](https://shizune.co/investors/profile/kirenaga-partners) — VC Fund, 1 deal together
- Tempus — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Katalyst Securities invest in?

Katalyst Securities invests primarily in Fitness, Medical and Genetics startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Katalyst Securities last invest?

The most recent investment recorded for Katalyst Securities closed in Nov 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co